Private Equity and Venture Capital Investing in the U.S. Cannabis Industry

Introduction

U.S. cannabis is a large, fragmented, state-by-state consumer and healthcare-adjacent market with unusually “legal-but-illegal” federal risk. In 2025, U.S. regulated cannabis sales (adult-use + medical) were $31.5B (adult-use $23.9B, medical $7.6B) with $39.1B forecast by 2029, per BDSA–sourced estimates.

Several investing realities dominate underwriting:

• State markets are maturing unevenly: the biggest legacy markets are dealing with price compression, tax friction, and illicit competition, while newer adult-use rollouts drive incremental growth. (Example: licensed California sales fell to $3.9B in 2025 from $4.2B in 2024 and $4.4B in 2023.)
• Capital formation is constrained: worldwide cannabis capital raises were ~$2.1B in 2025 (vs <$2.3B in 2024, >$1.9B in 2023, $4.3B in 2022, >$12B in 2021), while North American regulated cannabis M&A value rose to ~$2.1B in 2025 from $1.2B in 2024—a small M&A market relative to sector size.
• Federal rescheduling is the biggest swing factor, but it is not done: a rulemaking process to move marijuana from Schedule I to Schedule III has been underway since 2024, and a December 2025 executive order accelerated focus—but the order does not itself change federal law.
• Banking remains a bottleneck: banks that serve marijuana-related businesses still rely mainly on FinCEN’s 2014 guidance and related DOJ guidance; comprehensive federal “SAFE/SAFER Banking” legislation still has not passed the Senate as of early 2026 reporting.
• 280E is a structural tax drag while cannabis is Schedule I/II: Section 280E disallows deductions/credits for trafficking in Schedule I/II substances; operators generally can only reduce taxable income through COGS—and the IRS has issued interpretive guidance limiting how costs flow into COGS for many operators.
• Best-performing PE/VC strategies skew toward survivability + optionality: prioritize durable unit economics, compliance maturity, conservative leverage, and structures with downside protection (secured credit, royalties, structured equity) while preserving upside if rescheduling/banking reform improves cash taxes and capital costs.

Actionable north stars for investors:

• Underwrite to state-specific demand/supply, tax burden, and enforcement (illicit) realities—not top-line national narratives.
• Treat regulatory compliance and license integrity as core assets; price “license + compliance” explicitly in valuation and covenants.
• Build a rescheduling scenario stack (Status Quo vs Schedule III) that re-flows cash taxes, capex, and leverage capacity.

Market landscape

National market scale and category mix

For 2025, BDSA-estimated U.S. regulated cannabis sales totaled $31.5B, and the same source forecasts $39.1B by 2029. Category concentration is typical of mature consumer product markets: flower, vapes, edibles, and pre-rolls are large shares of spend (and are often the most price-competitive categories), affecting gross margin durability.

Two practical implications for PE/VC underwriting:

1. Price compression is not cyclical noise; in many states profit struggles reflect structural oversupply and competition regimes (open licensing vs limited licensing). This pushes investment value from “capacity” to “efficiency + brands + retail execution.”
2. Growth is increasingly state-rollout-driven, not purely penetration-driven—so market-entry timing, retail license availability, and competing with illicit operators can matter more than category innovation.

State market size and growth signals from official reporting

A recurring investor mistake is over-weighting “legalization headlines” and under-weighting how the state actually implemented (licensing, taxes, local opt-outs, enforcement). A few high-signal data points:

• California (largest market): licensed cannabis sales were $3.9B in 2025, down from $4.2B (2024) and $4.4B (2023), per state-tax data reporting.
• Illinois: official adult-use sales totals were $1.506B in 2025 vs $1.723B in 2024, alongside a switch to improved sales tracking via Metrc (important when building time series).
• Massachusetts: the regulator reported >$1.65B in adult-use sales in 2025 (record annual total, with sales fed from the state seed-to-sale system).
• Michigan: 2025 revenue was widely reported at roughly $3.17B, with lower revenue vs 2024 despite higher unit volume—consistent with severe price compression in open-license ecosystems.
• Ohio: first full year of adult-use saw total 2025 marijuana sales surpass $1.06B (adult-use + medical) based on state commerce data as summarized by industry reporting.

Chart of market-size trend in the largest state market

The California trend is a useful cautionary baseline: in mature markets, investors should expect margin defense and consolidation, not perpetual demand growth, unless illicit capture declines or tax burden falls.

State-by-state legalization and operating status

Below is a practical investing snapshot: adult-use legality, whether adult-use retail sales are operational, and whether a state has any medical program. The adult-use count (24 states + DC) is consistent with NCSL’s overview. Medical-program details change frequently and vary from comprehensive programs to narrow “low-THC/CBD-only” regimes; always confirm directly with the relevant state regulator during diligence.

Adult-use state count info: NCSL lists 24 adult-use states (plus DC), and highlights industry-relevant policy add-ons like record clearing/expungement that increasingly affects operator licensing and workforce mobility.

Regulatory and policy landscape

Federal vs state: why cannabis investing is structurally different

Even where fully legal under state law, “marijuana” remains illegal under U.S. federal law under the Controlled Substances Act, which is the foundational mismatch that drives banking friction, 280E, and public-market constraints.

A useful mental model for investors:

• States grant the license to operate and define unit economics (tax rates, local approvals, canopy caps, vertical integration rules, enforcement).
• The federal government defines the cost of capital and tax posture, because it drives banking access, anti-money-laundering duties, and 280E treatment.

Rescheduling status and what it would change

A DOJ/DEA rulemaking process to move marijuana from Schedule I to Schedule III has been active since 2024 (including formal hearing procedures in 2025). A December 2025 executive order directed a “fast-track” approach, but it did not itself reschedule marijuana.

From an investor standpoint, Schedule III would matter less for “headline legality” and more for cash-flow mechanics:

• 280E is tied to Schedule I/II trafficking. If cannabis moved to Schedule III, many operators would no longer fall under 280E’s disallowance rule (subject to how their activities are classified and future guidance).
• Improved after-tax cash flow would likely increase debt capacity, reduce default rates, and support higher valuation multiples—particularly for scale retailers and vertically integrated MSOs with large SG&A bases.

Best practice: treat rescheduling as a probability-weighted scenario, not a base-case certainty; price both the timing and the “implementation gap” risk (follow-on IRS/treasury guidance, state tax conformity, lender policy lag).

Banking: what actually exists today and what doesn’t

What exists today: financial institutions that bank cannabis generally operate under FinCEN’s 2014 guidance, which sets Bank Secrecy Act expectations for serving marijuana-related businesses, including SAR filings and customer due diligence aligned to federal enforcement priorities. A related DOJ memo on marijuana-related financial crimes was issued concurrently.

What still isn’t in place: comprehensive enacted federal cannabis banking reform (SAFE/SAFER Banking). As of early 2026 commentary, while versions have repeatedly advanced, the bill still has not passed the Senate.

Investor implications you should underwrite explicitly:

• Cash handling and cash logistics costs are persistent; they also amplify loss risks (theft, skimming, compliance failures).
• Payment acceptance and merchant services remain fragile and counterparty-dependent.
• Debt pricing and covenants remain more punitive than comparable consumer/health categories because many lenders cannot (or will not) participate.

280E: the tax rule that distorts margins and deal structures

Internal Revenue Code Section 280E states that no deduction or credit is allowed for a trade or business consisting of trafficking in Schedule I or II controlled substances (as defined in the Controlled Substances Act) when prohibited under federal or state law.

Key operational consequence: operators usually can reduce taxable income mainly through COGS, not ordinary business deductions, which can invert “good businesses” into cash-tax-negative outcomes. The IRS Office of Chief Counsel has issued guidance discussing how taxpayers subject to 280E determine COGS and referencing core cannabis tax cases (including CHAMP).

Hemp-derived THC crackdown: a parallel regulatory shock investors should watch

Congressional action in late 2025 narrowed the federal definition of hemp and effectively targeted intoxicating hemp-derived products; reporting indicates the change takes effect in November 2026 and is aimed at closing perceived Farm Bill loopholes around intoxicating cannabinoids.

Why PE/VC investors should care:

• It can shift consumer demand back toward state-regulated cannabis (positive for licensed operators) or expand illicit supply depending on enforcement.
• It introduces inventory, product-liability, and compliance risk for portfolio companies exposed to “hemp THC” SKUs or distribution.
• It changes the competitive landscape for beverages/edibles categories and could affect strategic buyer interest.

Timeline of federal inflection points for investors

Investment and fund structuring

Core fund structures and legal vehicles used in cannabis investing

Most cannabis-focused PE/VC capital is deployed through standard private fund architectures, adapted to cannabis-specific constraints: (i) state licensing “financial interest” rules, (ii) federal illegality-driven banking and custody friction, and (iii) 280E-driven cash-tax reality at the portfolio level.

At the fund level, the foundational U.S. securities framework is the same:

• Private funds commonly rely on Investment Company Act exclusions such as 3(c)(1) (≤100 beneficial owners) or 3(c)(7) (qualified purchasers), as described by the Securities and Exchange Commission.
• Offerings often rely on Regulation D exemptions such as Rule 506(b) (no general solicitation) or Rule 506(c) (general solicitation permitted with verification), per SEC small-business resources.
• The SEC’s 2023 “Private Fund Adviser Rules” were vacated by the Fifth Circuit; the SEC later acknowledged the vacatur publicly (important for compliance programs that were preparing for those requirements).

Table of typical fund structures and economics

The table below summarizes common structures and how they map to cannabis reality. Terms vary by manager track record, liquidity expectations, and strategy; treat the fee and carry ranges as market conventions rather than rules.

Structuring investments inside portfolio companies: patterns that matter

Because cannabis operators face high cash taxes and constrained refinancing options, “plain-vanilla equity” often underperforms debt-like structures on risk-adjusted returns in late-cycle state markets. In practice, many investors increasingly prefer:

• Senior secured or unitranche debt, with tight covenants and reporting.
• Royalties / revenue-share structures where enforceable.
• Structured equity (preferred equity with liquidation preference, PIK features, redemption rights where legal).

This preference aligns with public disclosures that the industry has faced declining capital availability and significant debt maturities, pushing distress and restructurings.

Deal making: terms, valuation, and diligence

Common term-sheet economics in cannabis PE/VC

Cannabis term sheets tend to be more protective than “traditional VC” because enforcement and tax risk is non-diversifiable. A practical summary:

Valuation: what works (and what breaks) under 280E + banking constraints

A robust cannabis valuation memo usually triangulates:

• State-specific unit economics (gross margin by category, wholesale vs retail mix, tax pass-through ability, local fees, labor).
• Cash-tax-adjusted EBITDA / “post-280E cash flow”: because conventional EBITDA can drastically overstate distributable cash under 280E.
• Comparable multiples using public comps as “sanity checks,” while recognizing public cannabis valuations are distorted by listing constraints and policy optionality.

Public-market signals (useful as guardrails):

• Viridian analysis indicates Tier 1 U.S. MSOs traded around 4.16x EV / 2025 consensus EBITDA, materially below many consumer/health sectors, while large Canadian LPs traded higher (example: 11.2x in the same commentary).
• Viridian’s valuation tracker commentary (Jan 2026) cites a median EV/2026 EBITDA multiple for a group of larger MSOs around mid-single digits, emphasizing the importance of adjusting enterprise value for tax liabilities in a post-280E scenario.

Practical underwriting recommendation: run two valuation bridges:

1. Status quo (Schedule I): depressed multiple + high cash taxes + expensive debt; and
2. Schedule III (if adopted): higher free cash flow + refinancing optionality + multiple expansion (with a discount for timing and implementation risk).

Due diligence checklist that actually catches losses

Instead of a generic checklist, cannabis diligence should be structured around “license integrity + compliance systems + cash and tax truth.” Below is a condensed but investor-grade framework.

Tax and accounting issues investors must underwrite

280E mechanics in brief

• 280E disallows deductions/credits for businesses trafficking in Schedule I/II controlled substances.
• Taxpayers can still reduce gross receipts by COGS, and IRS Chief Counsel guidance discusses how COGS interacts with 280E and references cannabis tax case law.

Investor takeaway: In cannabis, “EBITDA margin” is a secondary metric. The prime metric is cash available after taxes, compliance capex, and debt service.

COGS strategy and inventory costing: where investors see failures

The IRS Chief Counsel memo (CCA 201504011) is frequently referenced in cannabis accounting and tax planning because it addresses how taxpayers subject to 280E determine COGS and discusses constraints around cost capitalization concepts.

What PE/VC investors should demand (as diligence deliverables, not promises):

1. A defensible inventory costing policy with clean linkage to the seed-to-sale system and financial statements.
2. A written tax position memo mapping major COGS categories, method elections, and audit exposure.
3. A quantified rescheduling sensitivity: what happens to cash taxes if 280E goes away, and what happens to valuation if it doesn’t.

Financial reporting: the “truth gap” between statements and cash

Many operators show “adjusted EBITDA profitability” while remaining cash-tax constrained due to 280E and working-capital needs; public filings describe constrained capital availability and upcoming debt maturities that can force asset sales or restructurings.

Best practice for investors (GPs and LPs): require monthly cash waterfall reporting that starts with gross margin and ends with ending cash, explicitly including:

• cash taxes paid/owed,
• regulatory fees and settlement outflows,
• debt amortization and covenant headroom,
• inventory and receivables movements.

Exits, deal environment, risk mitigation, and ESG

Exit strategies and the current M&A/financing environment

Cannabis exits are still primarily M&A, structured recapitalizations, and secondary sales (often at the holding-company level). The public market exit path remains constrained because of federal illegality and listing limitations, which depress liquidity and widen bid-ask spreads for strategic transactions.

Two anchor data points for recent exit environment:

1. North American regulated cannabis M&A: approximately $2.1B in 2025 vs $1.2B in 2024 (Viridian figures cited in a public company’s SEC filing).
2. Worldwide cannabis capital raises: about $2.1B in 2025 (vs <$2.3B in 2024), far below the 2021 peak levels reported.

Chart of deal volume over time (capital raised)

(Values are rounded to the nearest tenth from “over/less than” disclosures in SEC filings.)

Practical exit-multiple reference points by sub-sector

Public comps and disclosed deal terms provide the most defensible “multiple anchors,” but note that cannabis multiples are highly regime-dependent (280E, banking, state saturation).

Risk factors and mitigation: an investor-grade framework

Public company risk disclosures highlight the biggest recurring cannabis risks: illicit competition, state tax and licensing structures, unit price declines compressing margins, constrained capital access, inflation and supply chain constraints, and heavy debt maturities.

A practical mitigation stack:

• Regulatory risk (state): Mitigate via multi-state diversification, licensing counsel in each state, and covenants tied to inspections, track-and-trace integrity, and renewal timelines.
• Federal policy risk (rescheduling/banking timing): Mitigate by structuring for downside (secured credit, liquidation preference, amortization) while preserving upside through warrants/convertibles and change-of-law clauses.
• 280E cash-tax risk: Mitigate by underwriting cash taxes explicitly, requiring tax reserves, and treating aggressive COGS strategies as an audit/settlement liability.
• Price compression and oversupply: Mitigate by stress testing to “mid-cycle” pricing, favoring assets with cost leadership or differentiated retail positioning, and limiting growth capex until unit economics prove resilient.
• Debt-maturity/refinancing risk: Mitigate through covenant visibility, maturity ladders, and proactive lender engagement; assume refinancing is expensive until federal risk clears.

ESG and social equity: what sophisticated LPs now expect

In cannabis, ESG is not a marketing layer; it is often embedded policy, shaping licensing and renewal risk. NCSL highlights record clearing and expungement trends tied to legalization, which increasingly influence workforce access and community-reinvestment expectations.

Best-in-class GP positioning typically includes:

• License-path alignment: invest alongside (not against) social equity frameworks where required; treat equity compliance as a renewal risk item.
• Workforce and community metrics: local hiring, wage standards, training spend, and documentation supporting claims (important during audits and press scrutiny).
• Governance: clear compliance ownership, incident reporting, and product-safety oversight.
• Environmental metrics: energy and water intensity per pound/unit produced; waste and packaging footprint (often material in indoor cultivation-heavy states).

Best practices playbook for GPs and LPs

For GPs (fund managers)

• Build a compliance-first operating partner bench: seed-to-sale + tax + licensing counsel are as central as CFO talent in this sector.
• Standardize a “cash truth” reporting package across portfolio companies (weekly cash + monthly cash waterfall + tax reserves).
• Use structures that survive policy volatility: prefer instruments with enforceable collateral and payment priority; treat pure equity as “policy optionality” capital.
• Write rescheduling into documents: change-of-law clauses, covenant resets, and pre-negotiated refinancing triggers.
• Do not outsource state-law diligence to a checklist: confirm “true party in interest” definitions, disclosure requirements, and local zoning exposure deal-by-deal.

For LPs (institutional and family office investors)

• Underwrite the GP’s compliance system, not just their IC deck: ask who signs filings, who owns audit readiness, and how state ownership reporting is managed across SPVs/co-invests.
• Demand reporting that separates operating performance from policy noise: include cash taxes, regulatory settlements, and debt maturities explicitly.
• Insist on concentration limits by state and by regulatory regime (open-license vs limited-license).
• Stress test liquidity: given muted capital raisings and smaller M&A volumes, assume exits take longer than standard VC/PE models.

A practical end-to-end investment workflow

(Each step is shaped by federal illegality, 280E, and state licensing enforcement.)